The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's (NVAX.O), opens new tab COVID-19 vaccine, the company told Reuters on Wednesday. The delay comes on the heels of the FDA's top vaccine scientist Peter Marks' exit from the agency, which will be effective April 5. Marks, who played a key role in developing COVID-19 vaccines during U.S. President Donald Trump's first term, was forced to resign, according to media reports. His departure led to a selloff in drugmakers' stocks on Monday and some analysts said it could put pressure on...